Influence of Beta Amyloid Imaging on Care of Patients Cognitive Complaints.

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

315 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-09-30

Study Completion Date

2013-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

When older patients develop cognitive problems - like memory loss - there may be any of several underlying causes, sometimes occurring in combination. Clinicians have a better chance of providing appropriate treatment if they understand what the cause of the problem is. A diagnostic tool can help the patient by helping the clinician to make a more accurate diagnosis. This study investigates whether a new diagnostic tool - beta amyloid imaging - may potentially improve medical practice. The tool can potentially improve practice only if it can influence clinical judgment. This study investigates whether the provision of beta amyloid imaging information influences clinical judgment. The investigators will conduct a survey that presents clinicians with descriptions of hypothetical older patients with cognitive complaints. Some of the respondents also receive beta amyloid imaging information. The investigators will test the investigators hypothesis that the information will affect diagnostic judgment and management recommendations by comparing the responses of clinicians who receive the beta amyloid information to the responses of clinicians who do not.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Amyloid PET in Patients With Mild Cognitive Impairment and Early Dementia

NCT06402370

MCI

RECRUITING

Imaging of Brain Amyloid Plaques in the Aging Population

NCT00950430

Alzheimer's Disease Dementia With Lewy Bodies Frontotemporal Dementia +1 more

ENROLLING_BY_INVITATION PHASE4

Tau PET Outcomes With Anti-amyloid Immunotherapies

NCT06723015

Cognitive Impairment, Mild Dementia, Mild Alzheimer Disease

ENROLLING_BY_INVITATION PHASE2

Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study

NCT02740634

Atypical Alzheimer's Disease Logopenic Progressive Aphasia (LPA) Posterior Cortical Atrophy (PCA) +5 more

RECRUITING NA

Amyloid-beta PET Imaging With 18F-92 in Alzheimer's Disease

NCT04926272

Alzheimer's Disease

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer's Disease Mild Cognitive Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Positive beta amyloid findings

Beta amyloid imaging results indicated a positive finding.

Group Type EXPERIMENTAL

Beta amyloid imaging

Intervention Type DEVICE

Negative beta amyloid findings

Beta amyloid imaging results indicated a negative finding.

Group Type EXPERIMENTAL

Beta amyloid imaging

Intervention Type DEVICE

No beta amyloid information

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Beta amyloid imaging

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Practicing clinicians describing their training and practice as any of the following: neurologist, geriatrician, psychiatrist.
* Included respondents must also attest that they are a physician who is experienced in the assessment and diagnosis of dementia.

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes